The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

 

Abbott Laboratories

NYSE: ABT
Last

(U.S.) $46.02

Today's change+0.38 +0.83%
Updated August 28 4:04 PM EDT. Delayed by at least 15 minutes.
 

Abbott Laboratories

NYSE: ABT
Last

(U.S.) $46.02

Today's change+0.38 +0.83%
Updated August 28 4:04 PM EDT. Delayed by at least 15 minutes.

Abbott Laboratories up (U.S.)$0.38

Abbott Laboratories closed up Friday by (U.S.)$0.38 or 0.83% to (U.S.)$46.02. Shares have lost 2.36% over the last five days, but are unchanged over the last year to date. This security has outperformed the S&P 500 by 9.06% during the last year.

Key company metrics

  • Open(U.S.) $45.61
  • Previous close(U.S.) $45.64
  • High(U.S.) $46.11
  • Low(U.S.) $45.21
  • Bid / Ask-- / --
  • YTD % change+2.22%
  • Volume9,191,586
  • Average volume (10-day)9,692,215
  • Average volume (1-month)6,671,012
  • Average volume (3-month)5,740,970
  • 52-week range(U.S.) $39.28 to (U.S.) $51.74
  • Beta0.73
  • Trailing P/E29.19×
  • P/E 1 year forward21.26×
  • Forward PEG2.40×
  • Indicated annual dividend(U.S.) $0.96
  • Dividend yield2.09%
  • Trailing EPS(U.S.) $1.58
Updated August 28 4:04 PM EDT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+11.67%

Based on its net profit margin of 11.67%, Abbott Laboratories is among the more effective companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX0.71%Sector:HealthcareIndustry:Pharmaceuticals - Diversified
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q2/2015Q1/2015Q4/2014Q3/2014
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedJun 30, 201506/30/2015Mar 31, 201503/31/2015Dec 31, 201412/31/2014Sep 30, 201409/30/2014
Revenue5,1704,8975,2905,104
Total other revenue--------
Total revenue5,1704,8975,2905,104
Gross profit2,9522,8172,9862,778
Total cost of revenue2,2182,0802,3042,326
Total operating expense4,4414,2874,4814,373
Selling / general / administrative1,7271,7301,7131,566
Research & development345313346305
Depreciation / amortization151156163132
Interest expense (income), net operating--------
Unusual expense (income)--8-4544
Other operating expenses, total--------
Operating income729610809731
Interest income (expense), net non-operating-44-37-43-35
Gain (loss) on sale of assets--------
Other--------
Income before tax986653802718
Income after tax786529632440
Income tax, total200124170278
Net income7842,292904538
Total adjustments to net income--------
Net income before extra. items786529632440
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items786529632440
Inc. avail. to common incl. extra. items7842,292904538
Diluted net income7842,292904538
Dilution adjustment--------
Diluted weighted average shares1,5041,5161,5221,520
Diluted EPS excluding extraordinary itemsvalue per share0.520.350.420.29
Dividends per sharevalue per share0.240.240.240.22
Diluted normalized EPSvalue per share0.520.350.390.31